Alpine Immune Sciences Inc (ALPN)
64.96
-0.01
(-0.02%)
USD |
NASDAQ |
May 16, 16:00
64.98
+0.02
(+0.03%)
Pre-Market: 20:00
Alpine Immune Sciences SG&A Expense (Quarterly): 7.271M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 7.271M |
December 31, 2023 | 6.374M |
September 30, 2023 | 5.443M |
June 30, 2023 | 5.007M |
March 31, 2023 | 5.398M |
December 31, 2022 | 4.389M |
September 30, 2022 | 4.61M |
June 30, 2022 | 4.194M |
March 31, 2022 | 4.775M |
December 31, 2021 | 4.544M |
September 30, 2021 | 3.47M |
June 30, 2021 | 3.29M |
March 31, 2021 | 3.256M |
December 31, 2020 | 3.049M |
September 30, 2020 | 2.728M |
June 30, 2020 | 3.344M |
March 31, 2020 | 1.778M |
December 31, 2019 | 2.102M |
September 30, 2019 | 2.467M |
June 30, 2019 | 2.553M |
March 31, 2019 | 2.345M |
Date | Value |
---|---|
December 31, 2018 | 2.514M |
September 30, 2018 | 1.857M |
June 30, 2018 | 1.883M |
March 31, 2018 | 2.108M |
December 31, 2017 | 1.207M |
September 30, 2017 | 1.932M |
June 30, 2017 | 2.592M |
March 31, 2017 | 2.781M |
December 31, 2016 | 2.168M |
September 30, 2016 | 1.879M |
June 30, 2016 | 2.172M |
March 31, 2016 | 2.367M |
December 31, 2015 | 2.337M |
September 30, 2015 | 1.822M |
June 30, 2015 | 1.387M |
March 31, 2015 | 1.298M |
December 31, 2014 | 0.664M |
September 30, 2014 | 0.49M |
June 30, 2014 | 0.594M |
March 31, 2014 | 0.5393M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.778M
Minimum
Mar 2020
7.271M
Maximum
Mar 2024
4.002M
Average
3.832M
Median
SG&A Expense (Quarterly) Benchmarks
Vertex Pharmaceuticals Inc | 342.70M |
Eliem Therapeutics Inc | 1.995M |
Regeneron Pharmaceuticals Inc | 689.00M |
Vera Therapeutics Inc | 7.912M |
Eyenovia Inc | 3.402M |